1.A Case of Refractory Sustained Ventricular Tachycardia with Dilated-Phase Hypertrophic Cardiomyopathy Treated by Left Ventriculotomy
Kenta Izumi ; Kiyoyuki Eishi ; Kouji Hashizume ; Seiichi Tada ; Kentaro Yamane ; Hideaki Takai ; Kazuyoshi Tanigawa ; Takashi Miura ; Shun Nakaji
Japanese Journal of Cardiovascular Surgery 2007;36(4):184-187
A 63-year-old man had been receiving medical treatment for hypertrophic cardiomyopathy (HCM) for 20 years. Sustained ventricular tachycardia (VT) had often occurred over the previous 2 years in spite of the administration of antiarrhythmic drugs. He therefore received an implantable cardioverter defibrillator (ICD). However, his symptoms did not improve thus dilated-phase HCM was diagnosed. Because sustained VT often occurred subsequently, the ICD had to be frequently used. An electrophysiological study (EPS) using the CARTO electroanatomical mapping system revealed the earliest activation site to be in the posterolateral wall of the left ventricle (LV). VT did not stop despite 2 endocardial catheter ablation procedures. Therefore, the VT foci was thought to be a reentry circuit on the epicardial side of the posterolateral LV wall. A part of the posterolateral LV wall that involved the reentry circuit was therefore resected. Since undergoing this surgical procedure, the patient has experienced no recurrence of VT during a follow-up period of 14 months.
2.Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review
Suguru KADOMOTO ; Kazuyoshi SHIGEHARA ; Hiroaki IWAMOTO ; Hiroshi YAEGASHI ; Kouji IZUMI ; Yoshifumi KADONO ; Atsushi MIZOKAMI
The World Journal of Men's Health 2020;38(1):132-136
3.Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma
Moito IIJIMA ; Noriyuki OKONOGI ; Nakako Izumi NAKAJIMA ; Yukie MOROKOSHI ; Hiroaki KANDA ; Taiju YAMADA ; Yusuke KOBAYASHI ; Kouji BANNO ; Masaru WAKATSUKI ; Shigeru YAMADA ; Tadashi KAMADA ; Daisuke AOKI ; Sumitaka HASEGAWA
Journal of Gynecologic Oncology 2020;31(2):19-
OBJECTIVE: Programmed cell death-ligand 1 (PD-L1) is expressed in tumor cells and has been shown to predict clinical outcomes of several types of malignancies. The aim of this study was to investigate the effects of carbon-ion (C-ion) beam irradiation on PD-L1 expression in human uterine cervical adeno/adenosquamous carcinoma (UCAA) cells and clinical samples and to identify the prognostic factors for outcomes after C-ion radiotherapy (CIRT).METHODS: The effects of C-ion irradiation on PD-L1 expression in human UCAA and cervical squamous cell carcinoma cells were examined by flow cytometry. We examined PD-L1 expression in UCAA biopsy specimens from 33 patients before CIRT started (pre-CIRT) and after 12 Gy (relative biological effectiveness [RBE]) irradiation (post-12Gy-C) in 4 fractions of CIRT to investigate the correlation between PD-L1 status and clinical outcomes.RESULTS: The PD-L1 expression was upregulated by C-ion beam in a dose-dependent manner in HeLa and SiHa cells through phosphorylated Chk1. The overall frequencies of pre-CIRT and post-12Gy-C PD-L1 positivity were 45% (15/33) and 67% (22/33), respectively. The post-12Gy-C PD-L1 expression was significantly elevated compared to the pre-CIRT PD-L1 expression. There was no significant relationship between the pre-CIRT PD-L1 status and clinical outcomes, such as local control (LC), progression-free survival (PFS), and overall survival (OS). However, the post-12Gy-C PD-L1 expression had better correlation with PFS, but not with LC and OS.CONCLUSION: CIRT can induce PD-L1 expression in UCAA and we propose that PD-L1 expression after starting CIRT may become as a predictive prognostic marker in CIRT for UCAA.
Antigens, CD274
;
Biopsy
;
Carcinoma, Squamous Cell
;
Disease-Free Survival
;
Flow Cytometry
;
Heavy Ion Radiotherapy
;
Humans
;
Radiotherapy
;
Treatment Outcome
;
Uterine Cervical Neoplasms
4.Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma
Moito IIJIMA ; Noriyuki OKONOGI ; Nakako Izumi NAKAJIMA ; Yukie MOROKOSHI ; Hiroaki KANDA ; Taiju YAMADA ; Yusuke KOBAYASHI ; Kouji BANNO ; Masaru WAKATSUKI ; Shigeru YAMADA ; Tadashi KAMADA ; Daisuke AOKI ; Sumitaka HASEGAWA
Journal of Gynecologic Oncology 2020;31(2):e19-
OBJECTIVE:
Programmed cell death-ligand 1 (PD-L1) is expressed in tumor cells and has been shown to predict clinical outcomes of several types of malignancies. The aim of this study was to investigate the effects of carbon-ion (C-ion) beam irradiation on PD-L1 expression in human uterine cervical adeno/adenosquamous carcinoma (UCAA) cells and clinical samples and to identify the prognostic factors for outcomes after C-ion radiotherapy (CIRT).
METHODS:
The effects of C-ion irradiation on PD-L1 expression in human UCAA and cervical squamous cell carcinoma cells were examined by flow cytometry. We examined PD-L1 expression in UCAA biopsy specimens from 33 patients before CIRT started (pre-CIRT) and after 12 Gy (relative biological effectiveness [RBE]) irradiation (post-12Gy-C) in 4 fractions of CIRT to investigate the correlation between PD-L1 status and clinical outcomes.
RESULTS:
The PD-L1 expression was upregulated by C-ion beam in a dose-dependent manner in HeLa and SiHa cells through phosphorylated Chk1. The overall frequencies of pre-CIRT and post-12Gy-C PD-L1 positivity were 45% (15/33) and 67% (22/33), respectively. The post-12Gy-C PD-L1 expression was significantly elevated compared to the pre-CIRT PD-L1 expression. There was no significant relationship between the pre-CIRT PD-L1 status and clinical outcomes, such as local control (LC), progression-free survival (PFS), and overall survival (OS). However, the post-12Gy-C PD-L1 expression had better correlation with PFS, but not with LC and OS.
CONCLUSION
CIRT can induce PD-L1 expression in UCAA and we propose that PD-L1 expression after starting CIRT may become as a predictive prognostic marker in CIRT for UCAA.
5.A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age.
Hiroaki IWAMOTO ; Kouji IZUMI ; Suguru KADOMOTO ; Tomoyuki MAKINO ; Renato NAITO ; Hiroshi YAEGASHI ; Kazuyoshi SHIGEHARA ; Yoshifumi KADONO ; Atsushi MIZOKAMI
Asian Journal of Andrology 2021;23(1):36-40
A standard modality for prostate cancer detection in men 75 years and older has not been established. A simple screening method for elderly patients is needed to avoid unnecessary biopsies and to effectively diagnose prostate cancer. A retrospective study was conducted on elderly patients who had prostate biopsy at Kanazawa University Hospital (Kanazawa, Japan) between 2000 and 2017. Of the 2251 patients who underwent prostate biopsy, 254 had clinically significant prostate cancer (CSPC) with a Gleason score (GS) of≥7 and 273 had a GS of <7 or no malignancy. In this study, patients aged 75 years or older were classified as elderly patients. GS ≥ 7 was characterized by a prostate-specific antigen (PSA) of the maximum area under the curve of 12 ng ml
6.A Case of Brugada Syndrome Treated With Percutaneous Epicardial Catheter Ablation
Masahiro OGAWA ; Yoshiyuki HYOUDOU ; Masayuki OKIJIMA ; Hirotaka INOUE ; Kouji KONDOU ; Yuki FUJII ; Atsuya SAKAIDE ; Keisuke TSUJIKAWA ; Kazuyoshi NISHIYAMA ; Ryouta TANI ; Izumi OHTA ; Mizuki ENDOU ; Kimitoshi SANO ; Kenji NAKAMAE ; Shinji KANEKO ; Masaya FUJITA ; Yousuke TATAMI ; Osamu KAWAGUCHI
Journal of the Japanese Association of Rural Medicine 2020;69(4):385-
This case report describes our first experience performing percutaneous epicardial catheter ablation for Burugada syndrome in our hospital. We describe the good results achieved in this case. The patient was a man in his 30s with no remarkable medical history. However, his family history was notable for the sudden death of his grandfather at age 37 years and his father at age 27 years. While asleep, the patient experienced convulsions and lost consciousness. During emergency transportation, defibrillation was performed 7 times by the ambulance crew. When the patient arrived at our hospital, sinus rhythm was observed on ECG. During resuscitation, Burugada syndrome was diagnosed based on ECG findings. On hospital day 6, an internal cardioverter defibrillator was implanted. After discharge, the defibrillator operated 10 times, so we opted for ablation treatment. Fractionated potential of over 150 ms was confirmed in the right ventricular outflow tract. A low voltage zone of <1 mV could be mapped, and the same site was cauterized a total of 46 times. As a result, ST segment amplitude decreased significantly in lead V1 on ECG. Percutaneous epicardial catheter ablation performed with reference to Nademanee’s report achieved good results in this case of Burugada syndrome.